This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • Barclays analyst Adrienne Yih downgraded the rating for Foot Locker, Inc. FL from Overweight to Equal-Weight and raised the price target from $14 to $24. Foot Locker shares closed at $23.90 on Thursday. See how other analysts view this stock.
  • UBS analyst David Dai downgraded Iovance Biotherapeutics, Inc. IOVA from Buy to Neutral and lowered the price target from $17 to $2. Iovance Biotherapeutics shares closed at $1.76 on Thursday. See how other analysts view this stock.
  • Baird analyst Joel Beatty downgraded Neurogene Inc. NGNE from Outperform to Neutral and slashed the price target from $38 to $24. Neurogene shares closed at $19.37 on Thursday. See how other analysts view this stock.

Considering buying FL stock? Here’s what analysts think:

  • Massive Demand & Disruptive Potential – Boxabl has received interest for over 190,000 homes, positioning itself as a major disruptor in the housing market.
  • Revolutionary Manufacturing Approach – Inspired by Henry Ford’s assembly line, Boxabl’s foldable tiny homes are designed for high-efficiency production, making homeownership more accessible.
  • Affordable Investment Opportunity – With homes priced at $60,000, Boxabl is raising $1 billion to scale production, offering investors a chance to own a stake in its growth.
Share Price: $0.80
Min. Investment: $1,000
Valuation: $3.5B

Read This Next:

Photo via Shutterstock

Loading...
Loading...
FL Logo
FLFoot Locker Inc
$24.08-0.16%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
57.33
Growth
25.79
Quality
Not Available
Value
81.68
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm

Comments
Loading...